Profile data is unavailable for this security.
About the company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
- Revenue in EUR (TTM)0.00
- Net income in EUR-195.39m
- Incorporated2013
- Employees69.00
- LocationAbivax SA7-11 Boulevard HaussmannPARIS 75009FranceFRA
- Phone+33 153830963
- Fax+33 494279261
- Websitehttps://www.abivax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galapagos NV | 286.92m | -443.87m | 1.87bn | 558.00 | -- | 0.7637 | -- | 6.51 | -6.74 | -6.62 | 4.35 | 37.13 | 0.0747 | 1.02 | 6.32 | 407,558.30 | -11.55 | -2.04 | -12.74 | -2.28 | 84.31 | -- | -154.70 | -27.56 | 8.56 | -- | 0.0031 | -- | 14.99 | -20.82 | 67.85 | -- | 12.44 | -- |
| BioArctic AB | 180.96m | 94.40m | 2.26bn | 122.00 | 28.51 | 14.50 | 22.98 | 12.48 | 11.30 | 11.30 | 21.64 | 22.22 | 1.04 | -- | -- | 17,909,460.00 | 54.12 | -2.87 | 67.19 | -3.22 | 97.08 | 86.59 | 52.17 | -12.41 | -- | -- | 0.0231 | -- | -58.22 | -1.80 | -177.24 | -- | 52.19 | -- |
| Genus plc | 773.76m | 22.20m | 2.32bn | 3.17k | 105.43 | 4.20 | 31.11 | 3.00 | 0.2874 | 0.2874 | 10.07 | 7.21 | 0.7132 | -- | 6.12 | 212,239.80 | 2.05 | 2.91 | 2.40 | 3.43 | -- | -- | 2.87 | 4.28 | 1.32 | 7.89 | 0.3584 | 70.94 | 0.5981 | 4.06 | 144.30 | -11.37 | -8.94 | 1.92 |
| BB BIOTECH AG | 576.12m | 182.32m | 2.79bn | 86.00 | 15.23 | 1.10 | -- | 4.85 | 3.02 | 3.02 | 9.58 | 41.83 | 0.2179 | -- | -- | 6,103,396.00 | 6.90 | -1.24 | 7.32 | -1.35 | 99.84 | 97.19 | 31.65 | -39.47 | -- | 1.50 | 0.00 | -- | 21,076.79 | -31.20 | 136.74 | -35.45 | -- | -11.94 |
| Zealand Pharma A/S | 1.23bn | 875.90m | 3.83bn | 440.00 | 4.39 | 1.85 | 4.35 | 3.12 | 91.00 | 91.00 | 129.24 | 215.72 | 0.6929 | 3.05 | 75.81 | 27,328,360.00 | 49.52 | -32.33 | 52.34 | -36.49 | 99.99 | 95.31 | 71.47 | -515.03 | 14.10 | -- | 0.0261 | -- | -81.71 | 8.69 | -53.30 | -- | -10.98 | -- |
| BACHEM HOLDING AG | 744.10m | 147.29m | 5.29bn | 2.29k | 35.76 | 3.54 | 27.76 | 7.11 | 1.80 | 1.80 | 9.07 | 18.14 | 0.3733 | 1.05 | 4.37 | 307,174.00 | 7.39 | 8.26 | 8.60 | 9.44 | 31.23 | 31.55 | 19.79 | 20.06 | 0.781 | 12.09 | 0.0428 | 52.54 | 4.84 | 14.05 | 7.50 | 17.29 | 56.91 | 7.21 |
| Abivax SA | 0.00 | -195.39m | 8.40bn | 69.00 | -- | -- | -- | -- | -3.09 | -3.09 | 0.00 | -0.7607 | 0.00 | -- | -- | 0.00 | -96.69 | -65.05 | -184.49 | -98.10 | -- | -- | -- | -- | -- | -21.71 | 2.33 | -- | -- | -- | -19.29 | -- | -7.33 | -- |
| Qiagen NV | 1.76bn | 358.03m | 8.92bn | 5.65k | 25.73 | 2.94 | 17.11 | 5.06 | 1.68 | 1.68 | 8.26 | 14.70 | 0.3488 | 2.66 | 5.45 | 311,492.70 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Eurofins Scientific SE | 7.30bn | 475.00m | 11.92bn | 65.00k | 25.77 | 2.56 | 10.81 | 1.63 | 2.54 | 2.54 | 38.86 | 25.54 | 0.6671 | 40.83 | 5.17 | -- | 4.32 | 6.78 | 5.48 | 8.46 | 21.40 | 23.08 | 6.48 | 10.10 | 1.03 | 6.34 | 0.492 | 21.89 | 4.96 | 6.05 | -25.14 | -6.70 | 8.60 | 1.15 |
| Genmab A/S | 3.02bn | 1.25bn | 16.38bn | 2.68k | 12.88 | 3.24 | 12.56 | 5.43 | 147.88 | 147.88 | 357.69 | 587.89 | 0.5535 | 16.68 | 3.60 | 8,407,228.00 | 22.89 | 17.70 | 25.72 | 19.07 | 94.27 | -- | 41.35 | 35.77 | 6.01 | -- | 0.0241 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
| Lonza Group AG | 7.17bn | 997.72m | 40.16bn | 19.77k | 40.26 | 3.92 | 23.51 | 5.60 | 12.94 | 13.51 | 93.02 | 133.07 | 0.3375 | 2.45 | 4.32 | 330,332.30 | 4.70 | 4.70 | 5.78 | 5.72 | 36.15 | 37.28 | 13.92 | 13.02 | 1.77 | 7.77 | 0.313 | 34.17 | -0.6541 | 7.70 | 42.92 | 4.48 | 7.13 | 10.76 |
Data as of Feb 16 2026. Currency figures normalised to Abivax SA's reporting currency: Euro EUR
11.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Darwin Global Management Ltd.as of 24 Jul 2025 | 4.26m | 5.43% |
| Deep Track Capital LPas of 11 Jul 2025 | 3.17m | 4.04% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 433.40k | 0.55% |
| Pictet Asset Management SAas of 31 Dec 2025 | 413.12k | 0.53% |
| CPR Asset Management SAas of 31 Dec 2025 | 178.15k | 0.23% |
| Saint Olive Gestion SNCas of 31 Dec 2025 | 162.45k | 0.21% |
| BNP Paribas Asset Management Europe SASas of 30 Jan 2026 | 132.19k | 0.17% |
| BlackRock Asset Management Deutschland AGas of 06 Feb 2026 | 118.27k | 0.15% |
| CA Indosuez Gestion SAas of 31 Dec 2025 | 109.88k | 0.14% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 94.18k | 0.12% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
